Rebecca Nash1, Kevin C Ward2, Ahmedin Jemal3, David E Sandberg4, Vin Tangpricha5, Michael Goodman2. 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States. Electronic address: rebecca.nash@emory.edu. 2. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States. 3. Surveillance and Health Services Research, American Cancer Society, Atlanta, GA, United States. 4. Department of Pediatrics & Communicable Diseases, University of Michigan School of Medicine, Ann Arbor, MI, United States. 5. Emory University School of Medicine, Atlanta, GA, United States; The Atlanta VA Medical Center, Atlanta, GA, United States.
Abstract
BACKGROUND: Transgender people and persons with disorders of sex development (DSD) are two separate categories of gender minorities, each characterized by unique cancer risk factors. Although cancer registry data typically include only two categories of sex, registrars have the option of indicating that a patient is transgender or has a DSD. METHODS: Data for primary cancer cases in 46 states and the District of Columbia were obtained from the North American Association of Central Cancer Registries (NAACCR) database for the period 1995-2013. The distributions of primary sites and categories of cancers with shared risk factors were examined separately for transgender and DSD patients and compared to the corresponding distributions in male and female cancer patients. Proportional incidence ratios were calculated by dividing the number of observed cases by the number of expected cases. Expected cases were calculated based on the age- and year of diagnosis-specific proportions of cases in each cancer category observed among male and female patients. RESULTS: Transgender patients have significantly elevated proportional incidence ratios (95% confidence intervals) for viral infection induced cancers compared to either males (2.3; 2.0-2.7) or females (3.3; 2.8-3.7). Adult DSD cancer patients have a similar distribution of primary sites compared to male or female patients but DSD children with cancer have ten times more cases of testicular malignancies than expected (95% confidence interval: 4.7-20). CONCLUSION: The proportions of certain primary sites and categories of malignancies among transgender and DSD cancer patients are different from the proportions observed for male or female patients.
BACKGROUND: Transgender people and persons with disorders of sex development (DSD) are two separate categories of gender minorities, each characterized by unique cancer risk factors. Although cancer registry data typically include only two categories of sex, registrars have the option of indicating that a patient is transgender or has a DSD. METHODS: Data for primary cancer cases in 46 states and the District of Columbia were obtained from the North American Association of Central Cancer Registries (NAACCR) database for the period 1995-2013. The distributions of primary sites and categories of cancers with shared risk factors were examined separately for transgender and DSDpatients and compared to the corresponding distributions in male and female cancerpatients. Proportional incidence ratios were calculated by dividing the number of observed cases by the number of expected cases. Expected cases were calculated based on the age- and year of diagnosis-specific proportions of cases in each cancer category observed among male and female patients. RESULTS: Transgender patients have significantly elevated proportional incidence ratios (95% confidence intervals) for viral infection induced cancers compared to either males (2.3; 2.0-2.7) or females (3.3; 2.8-3.7). Adult DSD cancerpatients have a similar distribution of primary sites compared to male or female patients but DSDchildren with cancer have ten times more cases of testicular malignancies than expected (95% confidence interval: 4.7-20). CONCLUSION: The proportions of certain primary sites and categories of malignancies among transgender and DSD cancerpatients are different from the proportions observed for male or female patients.
Authors: Melanie Blackless; Anthony Charuvastra; Amanda Derryck; Anne Fausto-Sterling; Karl Lauzanne; Ellen Lee Journal: Am J Hum Biol Date: 2000-03 Impact factor: 1.937
Authors: Kenneth H Mayer; Judith B Bradford; Harvey J Makadon; Ron Stall; Hilary Goldhammer; Stewart Landers Journal: Am J Public Health Date: 2008-04-29 Impact factor: 9.308
Authors: Martine Cools; Koen van Aerde; Anne-Marie Kersemaekers; Marjan Boter; Stenvert L S Drop; Katja P Wolffenbuttel; Ewout W Steyerberg; J Wolter Oosterhuis; Leendert H J Looijenga Journal: J Clin Endocrinol Metab Date: 2005-07-05 Impact factor: 5.958
Authors: J Pleskacova; R Hersmus; J W Oosterhuis; B A Setyawati; S M Faradz; M Cools; K P Wolffenbuttel; J Lebl; S L Drop; L H Looijenga Journal: Sex Dev Date: 2010-06-17 Impact factor: 1.824
Authors: Ash Alpert; Charles Kamen; Matthew B Schabath; Lauren Hamel; Julia Seay; Gwendolyn P Quinn Journal: J Clin Oncol Date: 2020-06-18 Impact factor: 44.544
Authors: Carolyn Moloney; Margaret Allen; Derek G Power; Richard M Bambury; Deirdre O'Mahony; Dearbhaile M O'Donnell; Seamus O'Reilly; Dearbhaile C Collins Journal: Oncologist Date: 2020-12-19
Authors: E Coleman; A E Radix; W P Bouman; G R Brown; A L C de Vries; M B Deutsch; R Ettner; L Fraser; M Goodman; J Green; A B Hancock; T W Johnson; D H Karasic; G A Knudson; S F Leibowitz; H F L Meyer-Bahlburg; S J Monstrey; J Motmans; L Nahata; T O Nieder; S L Reisner; C Richards; L S Schechter; V Tangpricha; A C Tishelman; M A A Van Trotsenburg; S Winter; K Ducheny; N J Adams; T M Adrián; L R Allen; D Azul; H Bagga; K Başar; D S Bathory; J J Belinky; D R Berg; J U Berli; R O Bluebond-Langner; M-B Bouman; M L Bowers; P J Brassard; J Byrne; L Capitán; C J Cargill; J M Carswell; S C Chang; G Chelvakumar; T Corneil; K B Dalke; G De Cuypere; E de Vries; M Den Heijer; A H Devor; C Dhejne; A D'Marco; E K Edmiston; L Edwards-Leeper; R Ehrbar; D Ehrensaft; J Eisfeld; E Elaut; L Erickson-Schroth; J L Feldman; A D Fisher; M M Garcia; L Gijs; S E Green; B P Hall; T L D Hardy; M S Irwig; L A Jacobs; A C Janssen; K Johnson; D T Klink; B P C Kreukels; L E Kuper; E J Kvach; M A Malouf; R Massey; T Mazur; C McLachlan; S D Morrison; S W Mosser; P M Neira; U Nygren; J M Oates; J Obedin-Maliver; G Pagkalos; J Patton; N Phanuphak; K Rachlin; T Reed; G N Rider; J Ristori; S Robbins-Cherry; S A Roberts; K A Rodriguez-Wallberg; S M Rosenthal; K Sabir; J D Safer; A I Scheim; L J Seal; T J Sehoole; K Spencer; C St Amand; T D Steensma; J F Strang; G B Taylor; K Tilleman; G G T'Sjoen; L N Vala; N M Van Mello; J F Veale; J A Vencill; B Vincent; L M Wesp; M A West; J Arcelus Journal: Int J Transgend Health Date: 2022-09-06
Authors: Alison M Berner; Dean J Connolly; Imogen Pinnell; Aedan Wolton; Adriana MacNaughton; Chloe Challen; Kate Nambiar; Jacob Bayliss; James Barrett; Christina Richards Journal: Br J Gen Pract Date: 2021-07-29 Impact factor: 6.302
Authors: Lihua Liu; Jean-Christophe N Rwigema; Ziwei Song; Myles Cockburn; Albert J Farias; Sue E Kim; Elizabeth A David Journal: Chest Date: 2020-12-04 Impact factor: 10.262
Authors: Iris de Nie; Chantal M Wiepjes; Christel J M de Blok; R Jeroen A van Moorselaar; Garry L S Pigot; Tim M van der Sluis; Ellis Barbé; Patrick van der Voorn; Norah M van Mello; Judith Huirne; Martin den Heijer Journal: BJU Int Date: 2021-08-30 Impact factor: 5.969